SEC Comment Letter 0000000000-23-006000 to NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: June 6, 2023 · CIK: 0001389545 · Accession: 0000000000-23-006000

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272304

Date

June 6, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

United States securities and exchange commission logo June 6, 2023 Justin Hall, Esq. Chief Executive Officer and General Counsel NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608

Re: NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 31, 2023 File No. 333-272304

Dear Justin Hall:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          June 6, 2023

       Justin Hall, Esq.
       Chief Executive Officer and General Counsel
       NovaBay Pharmaceuticals, Inc.
       2000 Powell Street, Suite 1150
       Emeryville, CA 94608

                                                        Re: NovaBay
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed May 31, 2023
                                                            File No. 333-272304

       Dear Justin Hall:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Daniel
Crawford at 202-551-7767 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Abby E. Brown, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io